Impact of Hesperetin in Combination With Sucrose on Energy Metabolism

November 27, 2023 updated by: Barbara Lieder, University of Vienna

Einfluss Des süßmodulierenden Polyphenols Hesperetin in Kombination Mit Saccharose Auf Die Blutglukose-Regulierung Und Energieaufnahme in Abhängigkeit Der Süßwahrnehmung

The aim of this cross-over intervention study is to investigate the influence of the sweet-modulating substance hesperetin in combination with sucrose in comparison to an equally sweet-tasting sucrose-only solution on markers of energy metabolism.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The study is designed as a randomised cross-over intervention study with two arms. The aim is to investigate the influence of a 10% sucrose solution, corresponding to the sugar content of a conventional soft drink, compared to an equally sweet-tasting 7% sucrose solution in combination with 50 mg/L of the polyphenol hesperetin, on time-dependent blood glucose fluctuations and ad libitum energy intake in metabolically healthy male volunteers.

To investigate the underlying mechanisms, the individual appetite score, metabolic and hormonal responses to the interventions and circulating extracellular vesicles and their miRNA composition will be measured. In addition, the participants' individual thresholds for sweet taste, preference and consumption for sweet-tasting foods such as sugar and sweeteners, and their body composition will be recorded as potential influencing factors.

Study Type

Interventional

Enrollment (Actual)

33

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Vienna, Austria, 1090
        • Christian Doppler Laboratory for Taste Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • male
  • healthy
  • non-smoking
  • normal taste responses towards sweet taste

Exclusion Criteria:

  • female
  • regular smokers
  • disturbed glucose and/or lipid metabolism
  • regular intake of medication
  • known allergies against one of the test compounds
  • ageusia
  • alcohol or drug addiction
  • intake of antibiotics within the past 2 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sucrose
10% (w/v) sucrose in water
10% sucrose corresponding to a regular soft drink
Other Names:
  • table sugar
Experimental: Hesperetin
7% (w/v) sucrose in water + 50 mg/L Hesperetin
increases sweetness of 7% sucrose solution to match sweetness of 10% sucrose solution
Other Names:
  • (2S)-3',5,7-Trihydroxy-4'-methoxyflavan-4-one
  • CAS number 520-33-2

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in blood glucose concentration
Time Frame: 15, 30, 60, 90, and 120 minutes after drinking the test solution
Change compared to baseline in blood glucose concentration [mg/dL] in plasma samples after drinking the test solution
15, 30, 60, 90, and 120 minutes after drinking the test solution
Change in appetite score
Time Frame: Difference between before and 120 minutes after drinking of the test solution
Change compared to baseline in the subjective rating of the individual feeling of hunger, fullness, as well as appetite for a snack or for something sweet on a digital visual analog scale in comparison to baseline
Difference between before and 120 minutes after drinking of the test solution
Change in food intake
Time Frame: 120 minutes after drinking of the test solution
Ad libitum food intake from a standardized breakfast
120 minutes after drinking of the test solution

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in blood glucose regulating hormones
Time Frame: 15, 30, 60, 90, and 120 minutes after drinking the test solution
Change compared to baseline in Insulin, Glucagon-like peptide 1, and Gastric inhibitory polypeptide concentrations [mmol/L] in plasma samples after drinking the test solution
15, 30, 60, 90, and 120 minutes after drinking the test solution
Change in satiety hormones
Time Frame: 15, 30, 60, 90, and 120 minutes after drinking the test solution
Change compared to baseline in Polypeptide Y, grehlin, cholecystokinin, and serotonin concentrations [mmol/L] in plasma samples after drinking the test
15, 30, 60, 90, and 120 minutes after drinking the test solution
Change in circulating miRNA
Time Frame: 15, 30, 60, 90, and 120 minutes after drinking the test solution
Change compared to baseline in circulating extracellular vesicles and their miRNA composition
15, 30, 60, 90, and 120 minutes after drinking the test solution

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Barbara Lieder, PhD, University of Vienna

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 31, 2023

Primary Completion (Actual)

June 30, 2023

Study Completion (Actual)

November 15, 2023

Study Registration Dates

First Submitted

January 17, 2023

First Submitted That Met QC Criteria

January 26, 2023

First Posted (Actual)

January 31, 2023

Study Record Updates

Last Update Posted (Actual)

November 28, 2023

Last Update Submitted That Met QC Criteria

November 27, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • 706014-2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hunger

Clinical Trials on Sucrose

3
Subscribe